Cancer of the pancreas is the fourth leading cause of death in the United States. Patients with pancreatic cancer have a poor prognosis. The majority of patients are unresectable at the time of diagnosis. The use of stereotactic body radiotherapy (SBRT) for pancreas cancer is promising with the clinical experience showing excellent local control. Major advantages of SBRT include intensified treatment and short treatment time allowing for continued intensive systemic chemotherapy.
KeywordsPancreatic Cancer Superior Mesenteric Artery Intensity Modulate Radiation Therapy Stereotactic Body Radiotherapy Gross Tumor Volume
- Chauffert B, Mornex F et al (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19(9):1592–1599PubMedCrossRefGoogle Scholar
- Klaassen DJ, MacIntyre JM et al (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern cooperative oncology group study. J Clin Oncol 3(3):373–378PubMedGoogle Scholar
- Moertel CG, Frytak S et al (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48(8):1705–1710PubMedCrossRefGoogle Scholar
- Moertel C, Frytak S, Hahn R et al (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone: gastrointestinal tumor study group. J Natl Cancer Inst 80(10):751–755Google Scholar